COMUNICADO: Avantium Intends to List on Euronext Amsterdam

Actualizado 22/10/2007 10:02:43 CET

AMSTERDAM, October 22 /PRNewswire/ --

-- Not for release, distribution or publication into or in the United States, Australia, Canada and Japan.

-- Positive Results With Next Generation Biofuels Trigger IPO Plans

Avantium, a leading technology company in the area of advanced high-throughput R&D, announces its intention to raise new funds through an initial public offering (the "IPO") and to apply for a listing on Eurolist by Euronext Amsterdam. Avantium intends to complete the IPO of its shares before the end of the year, subject to market conditions.

Avantium, established as a spin-off from Royal Dutch Shell in 2000, has developed advanced high-throughput R&D technology. Its proprietary technology enables the company to conduct many automated experiments in parallel on a very small scale, providing fast and cost effective research at superior success rates. Avantium has demonstrated the validity and commercial viability of its unique, patented technology and expertise by providing R&D services and tools to its clients in the energy, chemicals and pharmaceutical industries. The company services more than 70 companies worldwide, including many market leaders such as BP, Royal Dutch Shell, Sasol, Pfizer, Boehringer Ingelheim and GlaxoSmithKline.

Building on its track record and proven technology, Avantium plans to raise funds through an IPO to further grow its business by advancing its exciting product development programs in the fields of next generation biofuels and improved forms of existing drugs. Avantium achieved a key milestone by a successful proof-of-concept engine test of the company's next-generation, proprietary biofuel. Avantium released more details of its biofuels program today in a separate press release.

Tom van Aken, CEO of Avantium: "Through the support of our shareholders, Avantium has established a strong position in high-throughput R&D technology as proven by our blue-chip customer base. We are ready for the next step and intend to secure capital to finance our product development programs in the areas of biofuels and in improved crystal forms of existing drugs. The public offering will enable us to further realise our growth strategy and increase our visibility as an innovative company with a strong focus on renewable solutions."

Fortis has been appointed as global coordinator and bookrunner. The IPO is expected to take place before the end of the year and to consist solely of primary shares.

Profile Avantium

Avantium is a leading technology company in the area of advanced high-throughput R&D operating in the energy, chemicals and pharmaceutical industries. The company develops products and processes in the area of biofuels, bio-based chemicals and novel crystal forms of existing drugs by applying its proprietary, high-throughput R&D technology. Avantium has demonstrated the potential of this technology by providing R&D services and tools to more than 70 companies worldwide, including many of the world's largest energy, chemicals and pharmaceutical companies. Avantium has approximately 100 employees; its offices and head quarters are based in Amsterdam, the Netherlands.

www.avantium.com

This announcement is not an offer to sell or a solicitation of any offer to buy the securities of Avantium (the "Company", and such securities, the "Securities") in the United States or in any other jurisdiction.

The Securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States unless registered under the Securities Act or an exemption from such registration is available. No public offering of Securities of the Company is being made in the United States.

This communication is directed at and distributed only to (i) persons outside the United Kingdom, or (ii) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 or (iii) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. Any investment or investment activity to which this communication relates is available only to and will be engaged in only with such persons. This communication is confidential and is provided to recipients on a personal basis and must not be transferred or assigned or otherwise acted on or relied upon by persons within the United Kingdom who receive this communication (other than persons falling within (ii) and (iii) above).

This announcement does not constitute a prospectus. The offer to acquire securities pursuant to the proposed offering will be made, and any investor should make his investment, solely on the basis of information that will be contained in the prospectus to be made generally available in The Netherlands in connection with such offering. When made generally available, copies of the prospectus may be obtained at no cost from Fortis through the website of NYSE Euronext Amsterdam and the website of the Company (Dutch residents only).

For further information: For more information about this press release please contact: Citigate First Financial, José Tijssen / Claire Verhagen, Phone: +31-20-575 4010, Email: Jose.Tijssen@citigateff.nl / Claire.Verhagen@citigateff.nl

Mejora la comunicación de tu empresa con Europa Press Comunicación

Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies